The estimated Net Worth of Robert T Foster is at least $659 millier dollars as of 18 September 2023. Robert Foster owns over 1,600 units of Hepion Pharmaceuticals Inc stock worth over $37,853 and over the last 7 years he sold HEPA stock worth over $0. In addition, he makes $621,102 as Chief Executive Officer, Chief Scientific Officer et Director at Hepion Pharmaceuticals Inc.
Sign up
Robert Foster HEPA stock SEC Form 4 insiders trading
Robert has made over 4 trades of the Hepion Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of HEPA stock worth $8,960 on 18 September 2023.
The largest trade he's ever made was buying 25,000 units of Hepion Pharmaceuticals Inc stock on 8 December 2020 worth over $39,500. On average, Robert trades about 4,382 units every 92 days since 2017. As of 18 September 2023 he still owns at least 50,470 units of Hepion Pharmaceuticals Inc stock.
You can see the complete history of Robert Foster stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Foster biography
Dr. Robert T. Foster serves as Chief Executive Officer, Chief Scientific Officer, Director of the Company.D. serves as Chief Executive Officer, Chief Scientific Officer, Director of the Company. Prior to Hepion, he was Chief Executive Officer and Founder of Ciclofilin Pharmaceuticals Inc. from January 2014 until it merged with us on June 10, 2016. Prior to Ciclofilin Pharmaceuticals, he founded Isotechnika Pharma Inc. in 1993, where he was Chairman and Chief Executive Officer for 21 years. Dr. Foster was founding Chief Executive Officer and later, Chief Scientific Officer of Aurinia Pharmaceuticals, Inc., after Isotechnika acquired Aurinia. Dr. Foster is currently a Board member of Transcriptome Sciences Inc. Dr. Foster’s experience as an executive at a biotechnology company and his background as a scientist provides him with the leadership and management abilities which the Board believes qualifies him to be a director of our Company.
What is the salary of Robert Foster?
As the Chief Executive Officer, Chief Scientific Officer et Director of Hepion Pharmaceuticals Inc, the total compensation of Robert Foster at Hepion Pharmaceuticals Inc is $621,102. There are no executives at Hepion Pharmaceuticals Inc getting paid more.
How old is Robert Foster?
Robert Foster is 61, he's been the Chief Executive Officer, Chief Scientific Officer et Director of Hepion Pharmaceuticals Inc since 2018. There are 9 older and 1 younger executives at Hepion Pharmaceuticals Inc. The oldest executive at Hepion Pharmaceuticals Inc is Thomas Adams, 77, who is the Independent Director.
What's Robert Foster's mailing address?
Robert's mailing address filed with the SEC is #140, 14315 -118 AVENUE, , EDMONTON, A0, T5L 4S6.
Insiders trading at Hepion Pharmaceuticals Inc
Over the last 5 years, insiders at Hepion Pharmaceuticals Inc have traded over $0 worth of Hepion Pharmaceuticals Inc stock and bought 119,700 units worth $247,400 . The most active insiders traders include Gary S Jacob, Peter Wijngaard et John P Brancaccio. On average, Hepion Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $7,481. The most recent stock trade was executed by Peter Wijngaard on 24 November 2023, trading 5,000 units of HEPA stock currently worth $15,350.
What does Hepion Pharmaceuticals Inc do?
hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.
What does Hepion Pharmaceuticals Inc's logo look like?
Complete history of Robert Foster stock trades at Aurinia Pharmaceuticals Inc et Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals Inc executives and stock owners
Hepion Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Robert Foster,
Chief Executive Officer, Chief Scientific Officer, Director -
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.,
Pres, CEO & Director -
Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D.,
Pres, CEO & Director -
John T. Cavan,
Chief Financial Officer -
John Cavan,
Chief Financial Officer -
John Brancaccio,
Independent Director -
Timothy Block,
Independent Director -
Arnold Lippa,
Independent Director -
Thomas Adams,
Independent Director -
Gary Jacob,
Chairman of the Board -
Stephen Kilmer,
IR Contact Officer -
Peter Wijngaard,
Independent Director -
Dr. Stephen A. Harrison,
Member of Scientific Advisory Board & Consultant Medical Director -
Dr. John Z. Sullivan-Bolyai,
Part-Time Consultant -
Dr. Todd M. Hobbs M.D.,
Chief Medical Officer -
Dr. Patrick Mayo Ph.D.,
Sr. VP of Clinical Pharmacology -
Dr. Daniel Trepanier Ph.D.,
Sr. VP of Drug Devel. -
Sharen Pyatetskaya,
Director of Investor Relations -
Dr. Daren Ure Ph.D.,
Chief Scientific Officer -
Michael J. Purcell,
Director -
Kaouthar Lbiati,
Director